Samsung Biologics launches CHF 1.46 billion all-cash bid for Swiss drugmaker PolyPeptide
Question
Samsung Biologics launches CHF 1.46 billion all-cash bid for Swiss drugmaker PolyPeptide
Direct answer
The cross-border acquisition underscores Korean biotech’s global ambitions and could re-rate Samsung Biologics and peers on growth prospects, affecting instruments such as Samsung Biologics (KRX: 207940), the KOSDAQ biotech segment, and healthcare components of the KOSPI.
- Original publisher
- Market Ontology
- Evidence through
- 2026-07-20
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Samsung Biologics launches CHF 1.46 billion all-cash bid for Swiss drugmaker PolyPeptide”, revision 1, evidence through 2026-07-20. https://marketontology.com/market-events/2026-07-20/samsung-biologics-launches-chf-1-46-billion-all-cash-bid-for-swiss-drugmaker-pol-7ba943
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
Related
- 2026-10-21Bank of Korea holds its benchmark rate at 3.00% after two consecutive hikesKOSPI KTB 3Y USD/KRW
- 2026-10-20South Korea reports September exports reaching a record $121 billion as semiconductor demand drives growth005930.KS KOSPI KRW
- 2026-10-20South Korean data-centre infrastructure company Elice plunges 32% in its Seoul trading debutKORU KOSPI SOX
- 2026-10-20South Korean stocks suffer their steepest reported regional decline as investors retreat from technology sharesKOSPI KRW SAMSUNG ELECTRONICS
- 2026-10-19South Korean President Lee Jae-myung orders a policy review to restore normal trading conditions in the stock marketKOSPI KRW
- 2026-10-19South Korea's Kospi extends its technology-led selloff with a 1.6% declineKOSPI KRW/USD
- 2026-10-18Bank of Korea schedules October policy decision as markets assess whether to change its 3% base rateKOSPI KRWUSD KTB 3Y
- 2026-10-17South Korea orders tighter oversight of offshore platforms offering perpetual contracts linked to Korean stocksBTC KOSPI
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.